Lidice Bernardo
Overview
Explore the profile of Lidice Bernardo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
528
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hermida L, Valdes I, Gil L, Bernardo L, Lazo L, Romero Y, et al.
Arch Virol
. 2012 Feb;
157(5):987-91.
PMID: 22350649
We previously tested in monkeys the P64k-DomIII fusion protein of DEN-2 (PD5), combined with the serogroup A capsular polysaccharide (CPS-A) from N. meningitidis as an immunopotentiator. The results revealed the...
12.
Bernardo L, Pavon A, Hermida L, Gil L, Valdes I, Cabezas S, et al.
Vaccine
. 2011 Mar;
29(25):4256-63.
PMID: 21447316
Here we evaluated the suitability of the synthetic adjuvant IC31® to potentiate the protective capacity of PD5 protein (domain III of the envelope protein of dengue 2 virus fused to...
13.
Guzman M, Hermida L, Bernardo L, Ramirez R, Guillen G
Expert Rev Vaccines
. 2010 Jan;
9(2):137-47.
PMID: 20109025
A dengue vaccine should induce long-lasting, simultaneous protection to the four dengue viruses while avoiding the immune enhancement of viral infection. Domain III of the dengue envelope protein has been...
14.
Valdes I, Bernardo L, Gil L, Pavon A, Lazo L, Lopez C, et al.
Virology
. 2009 Sep;
394(2):249-58.
PMID: 19783271
Based on the immunogenicity of domain III from the Envelope protein of dengue virus as well as the proven protective capacity of the capsid antigen, we have designed a novel...
15.
Valdes I, Hermida L, Gil L, Lazo L, Castro J, Martin J, et al.
Int J Infect Dis
. 2009 Sep;
14(5):e377-83.
PMID: 19773190
Objective: The aim of the present work was to test the concept of the heterologous prime-boost strategy combining an infective dengue virus with a recombinant chimeric protein carrying domain III...
16.
Bernardo L, Fleitas O, Pavon A, Hermida L, Guillen G, Guzman M
Clin Vaccine Immunol
. 2009 Sep;
16(12):1829-31.
PMID: 19726617
In the present work, we evaluated the neutralizing capacity of the antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys against strains of...
17.
Cabezas S, Rojas G, Pavon A, Bernardo L, Castellanos Y, Alvarez M, et al.
Arch Virol
. 2009 Jun;
154(7):1035-45.
PMID: 19504165
The current study shows the usefulness of dengue-3- and dengue-4-specific phage-displayed antibody fragments as tools for viral detection and serotyping in sera from infected individuals. C6/36 HT cells were inoculated...
18.
Valdes I, Hermida L, Martin J, Menendez T, Gil L, Lazo L, et al.
Vaccine
. 2008 Dec;
27(7):995-1001.
PMID: 19100804
The main problem in the development of successful vaccines against dengue based on recombinant proteins is the necessity to use potent adjuvants to reach a proper functional immune response. Our...
19.
Izquierdo A, Bernardo L, Martin J, Santana E, Hermida L, Guillen G, et al.
Virus Res
. 2008 Sep;
138(1-2):135-8.
PMID: 18796319
Here, the antigenic specificity of the recombinant fusion proteins containing aa 286-426 of the dengue envelope protein fused to P64k from Neisseria meningitidis and the cross-reactive antibody response induced in...
20.
Alvarez M, Pavon-Oro A, Rodriguez-Roche R, Bernardo L, Morier L, Sanchez L, et al.
J Med Virol
. 2008 Aug;
80(10):1783-9.
PMID: 18712848
To evaluate the neutralizing antibody activity of a human sera panel against seven strains of the homotypic virus. Sera were collected from DENV-3 immune individuals. Two DENV-3 genotypes and strains...